However, to correctly answer this question, a well-planned study should be performed to definitively determine the nature of the relationship between these prophylactic agents and incidences of de novo hepatitis due to HBV cross infection in ABO-I-LDLT from HBc-Ab positive living donors to HBs-Ag negative recipients. The gene discussed is KRT88P; the disease is hepatitis A virus infection.